Related Experiment Video
Updated: Apr 24, 2026
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
[Efficacy of Ganciclovir Combined With Recombinant Human Interferon α-1b for Viral Encephalitis in Children]
Bing Han1, Lijing Zhao1, Xiao Han1
1（ 054000）Pediatric Third Department, Xingtai People's Hospital, Xingtai 054000, China.
Insights
Combination therapy with ganciclovir and recombinant human interferon α-1b effectively treats pediatric viral encephalitis. This treatment improves neurological function and cerebral hemodynamics without increasing adverse reactions.
Area of Science:
- Virology
- Pediatric Neurology
- Immunology
Background:
- Viral encephalitis poses a significant threat to children's neurological health.
- Standard treatments may have limitations in fully restoring neurological function and immune balance.
Purpose of the Study:
- To evaluate the efficacy of combining ganciclovir with recombinant human interferon α-1b for treating viral encephalitis in children.
- To compare the therapeutic outcomes, including symptom recovery, clinical efficacy, and neurological markers, against monotherapy.
Main Methods:
- A randomized controlled trial involving 160 pediatric patients diagnosed with viral encephalitis.
- Patients were divided into two groups: one receiving ganciclovir alone, the other receiving ganciclovir plus recombinant human interferon α-1b.
- Key parameters assessed included symptom resolution time, clinical effectiveness, EEG abnormalities, cerebral hemodynamics, neurological function markers, immune status, and inflammatory factors.
Main Results:
- The combination therapy group showed significantly shorter durations for fever, headache, vomiting, convulsions, and consciousness disturbance compared to the ganciclovir-only group.
- Higher clinical efficacy rates and lower EEG abnormality rates were observed in the combination therapy group.
- Combination therapy led to significant improvements in cerebral hemodynamics, neurological function markers (e.g., decreased NSE, increased NT-3), and immune function (e.g., increased IgG, IgE), while also reducing inflammatory markers (e.g., TNF-α, IL-1β).
Conclusions:
- Ganciclovir combined with recombinant human interferon α-1b is an effective treatment for pediatric viral encephalitis.
- This combination therapy improves cerebral hemodynamics and neurological function, modulates immune responses, and reduces inflammation without increasing adverse reactions.
- The findings support the use of this combination therapy as a beneficial treatment option for children with viral encephalitis.
Objective:
To explore the efficacy of ganciclovir combined with recombinant human interferon α-1b in the treatment of viral encephalitis in children.
Methods:
160 children with viral encephalitis admitted to third department of pediatrics of Xingtai People' s Hospital were selected, and divided into single group and combined group by random number table method, with 80 cases in each group. The single group was treated with ganciclovir, whereas the combined group was given ganciclovir combined with recombinant human interferon α-1b. Compare the time to recovery of symptoms in patients between groups. After 2 weeks of treatment, compare the clinical efficacy and EEG abnormalities between the two groups. The cerebral hemodynamics (mean blood flow velocity [Vm] and pulsatility index [PI] of anterior cerebral artery and posterior cerebral artery), neurological function (neuron specific enolase [NSE], neurotrophin3 [NT-3], nerve growth factor [NGF]), immune function (immunoglobulin A [IgA], IgG, IgE) and inflammatory factors (tumor necrosis factor α [TNF-α], interleukin β [IL-1β], interleukin 2 [IL-2]) before treatment and after 2 weeks of treatment were compared between groups, and the adverse reactions during treatment were recorded.
Results:
The disappearance durations of fever, headache, vomiting, convulsion, disturbance of consciousness and meningeal irritation in combined group were shorter than those in single group (P < 0.05). After 2 weeks of treatment, the total effective rate of clinical efficacy was higher in the combined group than in the single group (P < 0.05), the abnormal rate of EEG in the combined group was lower than that in the single group (P < 0.05). There was no statistically significant difference in the clinical effective rate between subgroups with different disease severity between the two groups of children (P > 0.05). The Vm and PI of anterior cerebral artery and posterior cerebral artery and levels of NSE, NGF, IgA, TNF-α, IL-1β and IL-2 were decreased in both groups, and the indicators in combined group were lower compared to single group (all P < 0.05). The levels of NT-3, IgG and IgE in both groups were enhanced after 2 weeks of treatment, and the levels were higher in combined group (all P < 0.05). There was no significant difference in the total incidence rate of adverse reactions between groups (P > 0.05).
Conclusion:
Ganciclovir combined with recombinant human interferon α-1b can effectively treat viral encephalitis in children, improve cerebral hemodynamics and neurological function, enhance immune function, and relieve inflammatory response, and it dose not increase adverse reactions.
More Related Videos
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
01:27Cytomegalovirus Disease
01:25Arboviral Encephalitis
01:26Encephalitis ll: Pathophysiology
01:19Encephalitis l: Introduction